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(rterial thrombosis is a major cause of morbidity and
ortality worldwide. Rupture or erosion of an atheroscle-
otic plaque stimulates platelet adhesion and aggregation
nd activation of the coagulation cascade, which result in
hrombus formation. The fate of an evolving thrombus is
argely determined by the balance between proaggregatory
nd procoagulant factors, on the one hand, and the fibrino-
ytic system, on the other (1). If the former prevail,
hrombus growth may result in complete arterial occlusion
ith potentially devastating consequences.
See page 2107
Recognition of the importance of platelet activation and the
oagulation cascade in this process has fueled the development
f a large number of drugs targeting different mechanisms of
latelet aggregation and thrombin generation. These drugs
ave become one of the mainstays of the prevention and
reatment of acute coronary syndromes (ACS) and other
ascular events (2). In addition, several bedside platelet func-
ion assays have recently been developed that have been able to
redict thrombotic complications and could be useful for
ailoring antiplatelet therapy (3,4).
In contrast with the wealth of information on prothrom-
otic factors, the role of endogenous fibrinolysis in arterial
hrombosis has often been neglected. This may have occurred,
n the one hand, because of the lack of specific drugs that
nhance fibrinolysis—apart from plasminogen activators in the
etting of acute myocardial infarction or ischemic stroke—
vailable for clinical use (1). On the other hand, studies
hat have investigated the association between fibrinolytic
tatus—by assessing genetic variants related to the activity
f the individual molecules involved or by directly measur-
ng their plasma levels—with the risk of thrombotic events
ave obtained conflicting results (5–8). In addition to the
arying methodologies, these inconsistencies have been
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RECAVA).ttributed to the marked variation of plasma levels of
brinolytic proteins both between and within subjects (1)
nd to nonfibrinolytic properties of these proteins with
pposing effects on atherothrombosis (8). Despite these
hortcomings, the evidence of early spontaneous reperfusion
n 15% to 20% of patients with ST-segment elevation
yocardial infarction (9) or ischemic stroke (10), and the
nding in the former that the culprit thrombus is often
eterogeneous in composition and age (11), support the
oncept of arterial thrombosis as a dynamic process in which
ndogenous fibrinolysis may play a prominent role.
The global thrombosis test (GTT) (Montrose Diagnostics,
ondon, United Kingdom) is a recently developed point-of-
are test aimed to assess simultaneously platelet reactivity and
pontaneous thrombolysis in non-anticoagulated blood (12). In
his test, blood is allowed to flow through a conic plastic tube
ontaining 2 steel ball bearings, a flat segment on the inner wall
f the tube preventing the balls from occluding the lumen.
latelets become activated by high shear stress by their passing
hrough the narrow gap between the larger ball bearing and the
all. Activated platelets aggregate and initiate coagulation in
he space downstream, and fibrin-stabilized platelet aggregates
cclude the second gap, stopping blood flow. If spontaneous
hrombolysis occurs, blood flow is restored. The test measures
he occlusion time (OT) and the lysis time (LT), which have
een shown to reflect, respectively, thrombus formation and
pontaneous thrombolysis (12).
In this issue of the Journal, Saraf et al. (13) assessed the
alue of the GTT in predicting major adverse cardiac events
MACE), defined as cardiovascular death, nonfatal myocar-
ial infarction, or stroke, after a 12-month follow-up of 300
CS patients on dual-antiplatelet therapy. A control sample
f 100 healthy people was also tested. As compared with
ntreated controls, ACS patients had more prolonged OT
nd LT, indicating less thrombogenicity and impaired
hrombolysis. Whereas OT was not associated with out-
ome, a prolonged LT was predictive of MACE even after
djusting for some baseline predictors. Receiver-operating
haracteristics curve analysis showed that LT significantly
iscriminated between patients with and without MACE
area under the curve  0.63). A cutoff of LT 3,000 s
rovided the best discrimination, and the risk increased
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May 11, 2010:2116–7 Measuring Endogenous Thrombolysis in ACSurther as LT increased. The net reclassification improve-
ent attained by including LT 3,000 s in a model with
ther predictors was estimated at 0.26 (p  0.001). In a
ubset of 100 patients, OT was weakly associated with the
esults of the VerifyNow P2Y12 assay (Accumetrics, San
iego, California), which were also not predictive of
ACE. The authors concluded that impaired endogenous
hrombolysis measured with GTT is an independent risk
actor for recurrent thrombotic events.
This is the first study addressing the prognostic usefulness of
global assessment of endogenous thrombolysis in patients
ith coronary artery disease, and the authors are to be credited
or their original approach. The results should prompt renewed
nterest in the role of endogenous fibrinolysis in the patho-
hysiology of ACS and in the potential utility of assessing
hrombolytic status in patients with this and other clinical
onditions. Nevertheless, owing to these potential important
mplications, some issues should be discussed.
First, the variability of LT measurements was relatively
igh (coefficient of variation of about 20%) both in control
ubjects and ACS patients. Although this variability concurs
ith previous studies with the same technique and with that
bserved by biochemical determinations of individual mark-
rs of fibrinolysis (1), it might compromise the interpreta-
ion of the results in a given patient, particularly if they are
lose to the proposed cutoff value.
Second, as the authors acknowledged, that GTT was
erformed only once during the acute phase represents a
imitation. A residual effect of the antithrombotic regimens
sed in the initial management of patients on platelet function
ould have affected OT and its relation to MACE. Similarly,
he value of LT in predicting complications might have been
ifferent had patients been tested at a later stage. In this
espect, significant changes in the levels of fibrinolytic markers
ave been described during the first days after an ACS (14).
Finally, but not less important, the sample size was
elatively small for a study of this nature. The low number
f events obliged the authors to restrict the multivariable
djustment to a reduced number of predictors. Ejection
raction was not systematically recorded, and no adjustment
as intended for heart failure, a variable with a strong
ssociation with adverse events in ACS patients (15,16).
his is a significant limitation because the incremental
rognostic value of LT might have been substantially lower
fter adequate adjustment for all the clinical predictors.
Hopefully, future studies will shed light on these issues.
eanwhile, the present results should encourage reassess-
ent of the role of endogenous thrombolysis not only in
schemic heart disease but also in other conditions suspected
o be influenced by the fibrinolytic status such as deep vein
hrombosis or bleeding disorders. To date, no specific
odulators of the fibrinolytic status are available for chronic
se in humans (1). However, a more precise knowledge of
ts role in these clinical conditions, to which the study of
araf et al. (13) has contributed significantly, is a prerequi- cite for the future development of effective therapies target-
ng endogenous thrombolysis.
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